OXIGENE INC. (OXGN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OXIGENE INC. (OXGN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (232)	8/17/2001 1:33:07 PM
From: nigel bates	of 273

I take it you saw this (courtesy of noprofileavail on Yahoo)- LONDON, Aug 17 (Reuters) - Robertson Stephens said on Friday it had cut its rating on U.S. drugmaker Oxigene Inc. to "market perform" from "buy", due to uncertainty regarding the company's cancer drug, Combrestatin. Robertson Stephens analysts said they believed Phase One trials for the drug, which is designed to fight cancer by choking off blood flowing to tumours and is licensed to Bristol Myers Squibb, may be suspended. "While neither Bristol Myers Squibb or Oxigene have commented on the specific progress of the trial, we have gathered information that suggests that the trial may be temporarily suspended, possibly as a result of one or more incidences of cardiotoxicity," they said in a research note. "Oxigene's management has been unable to deny thses assertions outright due to a lack of information from Bristol Myers," they added. "Although we believe Oxigene remains very cheap .., the current situation creates enough uncertainty that we are unable to recommend the stock to investors at this time," they said. Shares in Oxigene closed at $3.56 on Thursday.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next